These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Enfortumab vedotin in the treatment of urothelial cancers and beyond. Wong RL; Yu EY Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781 [TBL] [Abstract][Full Text] [Related]
14. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844 [TBL] [Abstract][Full Text] [Related]
15. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance. Aggen DH; Chu CE; Rosenberg JE Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589 [TBL] [Abstract][Full Text] [Related]
17. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer. Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592 [TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729 [TBL] [Abstract][Full Text] [Related]
19. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review. Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]